Alumis (ALMS) Preferred Stock Liabilities (2023 - 2024)
Alumis (ALMS) reported Preferred Stock Liabilities of $639.2 million for Q2 2024, up 86.28% year-over-year from $343.2 million in Q3 2023, and up 28.99% on a QoQ basis from $495.6 million in Q1 2024.
Alumis (ALMS) has 2 years of Preferred Stock Liabilities data on file, last reported at $639.2 million in Q2 2024.
- Quarterly Preferred Stock Liabilities rose 86.28% year-over-year to $639.2 million in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $639.2 million (up 86.28% YoY) and the FY2023 annual result came in at $375.4 million, changed N/A from the prior year.
- Preferred Stock Liabilities rose to $639.2 million in Q2 2024 per ALMS's latest filing, from $495.6 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $639.2 million in Q2 2024 and bottomed at $343.2 million in Q2 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Alumis | 1.84 Bn | 1.75 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 639.24 Mn |
| Mar 31, 2024 | 495.58 Mn |
| Dec 31, 2023 | 375.37 Mn |
| Sep 30, 2023 | 343.15 Mn |
| Jun 30, 2023 | 343.15 Mn |